Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome (CELEST)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Laboratoires Innothera
Sponsor:
Collaborators:
University Hospital, Grenoble
Floralis
Information provided by (Responsible Party):
Laboratoires Innothera
ClinicalTrials.gov Identifier:
NCT01578122
First received: April 13, 2012
Last updated: January 15, 2014
Last verified: January 2014
  Purpose

Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention. Therapeutic trials evidenced that elastic compression stockings (ECS) applying 30-40mmHg of pressure at the ankle reduced the rate of PTS by 50%. Although ECS are unlikely to cause harm, in clinical practice, compliance to this treatment appears to be low as ECS may be difficult to apply and to wear.

ECS with a lighter compression strength (20-30mmHg) might be easier to apply and be more comfortable. This could favor a better compliance.

CELEST is a randomized, multicentre, double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle


Condition Intervention Phase
Deep Vein Thrombosis
Post-thrombotic Syndrome
Device: compression stockings 25mm Hg
Device: compression stockings 35 mm Hg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg

Resource links provided by NLM:


Further study details as provided by Laboratoires Innothera:

Primary Outcome Measures:
  • To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg) [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    cumulative incidence 24 months after inclusion of PTS apparition defined by the Villalta score > or equal to 5. A visual guide will be given to investigators to assist them and standardize PTS evaluation. Investigators will receive a Villalta training during set up visits.


Secondary Outcome Measures:
  • superiority of targeted pressure at 35 mm Hg for compliant patients. Analysis of the primary endpoint per protocol amongst patients responding to the definition of compliance for compression scheduled by randomization [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    analysis of primary endpoint (cumulative incidence of PTS) amongst patients responding to the definition of observance for compression scheduled by randomization. It means a per protocol analysis. The per protocol analysis defined as follow : patients ideally compliant (see next secondary outcome measure with self declaration of compression carrying superior or equal to 80 % especially)and patients with respect to randomization.

  • Superiority of 25 mm Hg on the therapeutic compliance criterion [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    Superiority of 25 mm Hg on the therapeutic compliance criterion at 24 months

    Compliance is defined by 3 conditions :

    1. Morisky-Green score adjusted between 0 and 2
    2. because of French clinical practices it should be pertinent to take into consideration 2 compliance type :

      1. ideal compliance : Self declaration ≥ 80 % (reference PRANDONI)
      2. adequate compliance : self declaration between 50 and 79% for (French references Delluc and Optimev study)
    3. return of used stockings ≥ to 80%

  • superiority of 25 mm Hg for constraints related to compression and chronic venous insufficiency quality of life (CIVIQ) [ Time Frame: 3 months, 12 months, 24 months ] [ Designated as safety issue: No ]
    CIVIQ quality of life (CIVIQ 20) specific to chronic venous insufficiency at 3 months, 12 months and 24 months and questionnaire about constraints of compression stockings.

  • non inferiority of 25 mm Hg for the comparative evaluation of the symptomatic effect of short-term compression (pain, sensation of oedema) form baseline to 3 months [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Comparison of evolution at short-term (3 months) of venous thrombosis symptoms (pain, oedema feeling). Self assessment by VAS of pain and oedema feeling once a week during 3 months. Assessment by the investigator at inclusion and during visit at 3 months (ankle measurement, clinical signs) will be done also. A statistical analysis will be done as soon as 3 months follow up data will be verified to evaluate symptoms evolution due to deep venous thrombosis.

  • Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire [ Time Frame: 3months, 12 months, 24 months ] [ Designated as safety issue: No ]
    Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire (EQ5D)

  • non inferiority of 25 mm Hg for the intensity of long term chronic venous insufficiency symptoms (12 months and 24 months) [ Time Frame: 12 and 24 months ] [ Designated as safety issue: Yes ]

    Long term assessment of evolution and intensity of symptoms (pain, oedema feeling) related to potential post-thrombotic syndrome apparition

    • Monthly self-assessment by VAS for pain and oedema feeling during 24 months. It will be done at the end of each month and will focus on symptoms intensity (last week of the month)
    • An assessment will be done by investigator, in addition of previous criterion, at 12 and 24 months
    • Assessment with the Ginsberg score (interview by the investigator at 12 and 24 months)
    • Comparison of averages on Villalta score (quantitative)

  • non inferiority of 25 mm Hg for the onset of permanent trophic disorders [ Time Frame: 3 months, 12 and 24 months ] [ Designated as safety issue: Yes ]
    CEAP classification evaluated by investigator at 3, 12 and 24 months

  • non inferiority of 25 mm Hg for the onset of sequalae or post thrombotic residues on an duplex scan at 3 months, 12 and 24 months [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: Yes ]

    Assessment by duplex scan of deep and superficial veins at 3, 12 and 24 months

    • Assessment by duplex scan of deep reflux (>1s in femoral vein, and/or popliteal vein, tibio peroneal trunck)
    • Assessment by duplex scan of superficial reflux (> 0.5s in great saphenous vein, small saphenous vein, perforating veins)
    • Assessment by echographic score of thickness and location of residual thrombus
    • Assessment by duplex scan of re-canalization of collectors trunks and/or parietal sequalae

  • testing for the prognostic factors of the onset post thrombotic syndrome and comparison of the onset kinetics of post thrombotic syndrome [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

    variables tested as prognostic factors of post thrombotic syndrome apparition :

    • location of the upper pole of thrombus
    • kinetic of thrombus lysis by duplex scan at 3 months
    • Idiopathic nature of TED
    • Delay of diagnostic of deep venous thrombosis
    • Initial intensity of deep venous thrombosis symptoms
    • Initial evolution of symptoms of deep venous thrombosis between J0 and 3 months
    • Persistence of the symptoms at 3 months
    • Patient's characteristics
    • Kinetic of of Villalta score apparition ≥ 5 by survival curve
    • Kinetic of post thrombotic syndrome apparition by Villalta score

  • test for key factors in good compliance [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Compliance evaluation according to the 3 axes defined on third outcome measure and research of determinants of good compliance by specific questionnaire

  • Adverse events [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    description and comparison of the incidence of adverse events including unexpected adverse events, events expected with this type of disease (recurrence of the venous thromboembolic disease, recurrence of deep vein thrombosis, pulmonary embolism, superficial venous thrombosis, venous ulcer) and events possibly related to the study treatment (arterial decompensation passing to Lerich stage III or IV, skin intolerance)

  • Subgroups analysis of the primary objective and secondary objectives according to the gender stratification criterion and age [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Stratification on age (more or less than 65 years-old) for testing the hypothesis by subgroups analysis of the benefit of a better adaptation of compression 25 mm Hg on older subjects, as suggested by S. Khan.

  • superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome. Outcome measure identical to primary endpoint

  • sensitivity analysis of primary endpoint excluding patients with a differential diagnosis can explain a Villalta score ≥ 5 [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    sensitivity analysis of primary endpoint excluding patients with a differential diagnosis which could explain a Villalta score ≥ 5. Outcome measure identical to primary endpoint


Estimated Enrollment: 350
Study Start Date: June 2012
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 25mmHg ECS
Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
Device: compression stockings 25mm Hg

Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.

Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).

Other Names:
  • ACTYS 25® for women
  • LEGGER 25® for men
Active Comparator: 35mm Hg ECS
Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
Device: compression stockings 35 mm Hg
Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
Other Names:
  • ACTYS 35® for women
  • LEGGER 35® for men

Detailed Description:

CELEST trial is a controlled, randomized, multicentre, non-inferiority double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle. Patients with a first acute symptomatic proximal DVT will be randomized to wear for two years either ECS applying 25mmHg of targeted pressure at the ankle or ECS applying 35mmHg of targeted pressure at the ankle. All patients will be prescribed anticoagulants for at least three months. The primary outcome will be the rate of PTS assessed with the Villalta scale in both arms of the study during the 2 years study period. Rate of compliance,severity of PTS and quality of life in both groups will constitute the main secondary outcomes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Patient (male/female) at least 18 years old
  • Patient presenting with an initial episode of proximal deep vein thrombosis (DVT) confirmed by an additional examination (echo-Doppler scan) taken no more than 8 days previously :

the proximal character defined by a DVT from the collecting trunk extending from the tibial-peroneal trunk to the inferior vena cava inclusive the unilateral character concerns only the proximal part. Patients with a distal DVT on the contralateral member the day of diagnosis can be included The notion of initial episode concerns only the proximal part. Patients with a preceding DVT limited to distal part can be included

  • with no trophic disorders at baseline (CEAP class 4, 5 or 6 excluded)
  • with or without pulmonary embolism
  • Patient capable of benefiting from anticoagulant therapy of at least 3 months duration
  • Available to participate in a clinical trial with a 24-month follow-up period and for which a delivery of study products may be possible throughout its participation (delivery possible only in Metropolitan France)
  • Life expectancy greater than 24 months
  • Volunteer to take part in the study, having signed the consent form after receiving sufficient information and the information leaflet
  • Person affiliated to social security or the recipient of a similar scheme.

non inclusion criteria

  • Patients with at least one of these contraindications to compression treatment:

    • phlegmasia cerulea dolens,
    • septic thrombosis,
    • product intolerance, allergic reaction to one of the components
    • Arteritis obliterans stage III and IV of the lower limbs (IPS<0.6),
    • Micro-angiopathy, advanced diabetes,
    • Decompensated heart failure,
    • Skin infections: anti-infective treatment must precede compression therapy,
    • Weeping skin diseases of the leg.
    • Compression treatment technically impossible during the study
  • Patients presenting with bilateral venous thrombosis of the lower limbs.
  • Patient having received fibrinolytic treatment, mechanical thrombo-aspiration or venous repermeation surgery for venous thrombosis justifying inclusion
  • Patients having undergone mechanical interruption of the inferior vena cava.
  • Patients for whom long-term elastic compression for the treatment of lymphatic venous insufficiency (patients with lymphoedema), for instance, is indicated prior to DVT. Patients with elastic compression for primary thromboprophylaxis of thromboembolic disease (TED) are eligible.
  • Patients presenting with oedema unrelated to venous insufficiency or in whom oedema is likely to develop within 2 years.
  • Patients receiving diuretic treatment for more than 3 months due to heart failure.
  • Pregnant women
  • Person deprived of liberty by a legal or administrative decision, person under legal protection.
  • Patient currently participating in a clinical trial or having taken part in a clinical trial in the month preceding inclusion
  • Patient presenting with a history of mental or psychiatric illness or any other factor restricting his/her ability to participate in an informed manner and in compliance with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01578122

Contacts
Contact: Jean-Luc BOSSON, MD, PhD + 33 476765040 JLBosson@chu-grenoble.fr
Contact: Carole ROLLAND + 33 476765040 CarRolland@chu-grenoble.fr

  Show 62 Study Locations
Sponsors and Collaborators
Laboratoires Innothera
University Hospital, Grenoble
Floralis
Investigators
Principal Investigator: Jean-Luc BOSSON, MD, PhD CIC Grenoble
  More Information

Additional Information:
Publications:

Responsible Party: Laboratoires Innothera
ClinicalTrials.gov Identifier: NCT01578122     History of Changes
Other Study ID Numbers: CVE301-10 (Themas) : DCIC/1028, 2010-A01078-31
Study First Received: April 13, 2012
Last Updated: January 15, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: The Commission nationale de l’informatique et des libertés
France: Conseil National de l'Ordre des Médecins

Keywords provided by Laboratoires Innothera:
post-thrombotic syndrome
prevention
deep vein thrombosis
elastic compression stockings
compliance
quality of life

Additional relevant MeSH terms:
Phlebitis
Syndrome
Thrombosis
Venous Thrombosis
Postphlebitic Syndrome
Postthrombotic Syndrome
Disease
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Venous Insufficiency

ClinicalTrials.gov processed this record on September 18, 2014